Hologic intends to invest in assay development for Mobidiag's Novodiag PCR platform, which provides high-level multiplexing to detect infectious disease organisms.
Diagenode already sells more than 30 real-time PCR tests that are CE-marked for the detection of bacteria, parasites, and viruses for multiple infectious diseases.
Hologic said that the transaction further strengthens its molecular diagnostics business by expanding its international capabilities, among other benefits.
Within its diagnostics division, the firm posted molecular diagnostics revenue of $995.3 million, up more than fivefold from $178.5 million in fiscal Q1 2020.
The expert body now recognizes the test's ability to predict whether early-stage breast cancer patients will benefit from extended, adjuvant endocrine therapy.
Among firms presenting on the first day, Roche provided insights into its COVID-19 testing business, and Guardant said it plans to launch a comprehensive tissue sequencing assay.
The firm's Diagnostics division expects to post $1.13 billion in revenues for fiscal Q1 2021, up 262 percent from $312.0 million in the year-ago period.
